Business
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
Phase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025 Initial data from the Phase 1 study of RP-A601 for
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":"\nPhase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025\n\nInitial data from the Phase 1 study of RP-A601 for PKP2-ACM anticipated May 2025\n\nIND submission for BAG3-DCM program expected mid-year 2025\n\nSarbani Chaudhuri appointed Chief Commercial & Medical Affairs Officer\n\nCash, cash equivalents and investments of approximately $318.2M; expected operational runway into the fourth quarter of 2026\n\n CRANBURY, N.J.--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ending March 31, 2025.\n\n\"Rocket maintained strong momentum during the first quarter, and we look forward to sharing updates of our recent progress starting with initial data from the Phase 1 study of RP-A601 for PKP2-ACM this month, followed by an update on our Danon disease program in mid-year 2025. We also remain on track to submit an IND for BAG3-DCM. We continue to prioritize our current resources towards our AAV cardiovascular programs, which we see as holding the greatest potential to deliver transformative therapies to patients and provide the strongest value to shareholders,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. “As we continue into 2025, we remain steadfast in preserving resources and safeguarding financial health to keep on advancing our mission of seeking gene therapy cures for patients with devastating diseases, and as result have expanded our runway into the fourth quarter of 2026.”\n\nRecent Pipeline and Operational Updates\n\n\nPhase 2 pivotal study of RP-A501 for Danon disease is ongoing.\n\n\nProgram update anticipated in mid-year 2025 and a clinical data readout expected in mid-year 2026. Details of the Phase 2 pivotal study can be found at www.ClinicalTrials.gov under NCT identifier NCT06092034.\n\n\nIn March, the largest longitudinal natural history study of Danon disease to date was published in the Journal of the American Heart Association (JAHA), revealing key insights into the distinct cardiac patterns of Danon disease patients, showing earlier, more severe heart issues in male patients, while also noting that many fem...